ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for charts 登録してリアルタイムのチャート、分析ツール、価格を入手してください。
Daiichi Sankyo Co Ltd (PK)

Daiichi Sankyo Co Ltd (PK) (DSKYF)

31.55
3.01
(10.56%)
終了 11月20日 6:00AM

リアルタイムのディスカッションと取引のアイデア: 当社の強力なプラットフォームで自信を持って取引できます。

主要統計と詳細

通貨
31.55
買値
28.90
売値
31.55
出来高
7,288
28.15 日の範囲 31.55
25.95 52 週間の範囲 44.64
時価総額
前日終値
28.536
始値
28.31
最終取引時間
財務取引量
US$ 216,759
VWAP
29.742
平均取引量 (3 か月)
3,463
発行済株式数
1,916,787,029
配当利回り
14,703.71%
PER
0.30
1 株当たり利益 (EPS)
104.72
歳入
1.63T
純利益
200.73B

Daiichi Sankyo Co Ltd (PK) について

セクター
Pharmaceutical Preparations
業界
Pharmaceutical Biolog/vaccines
ウェブサイト
本社
Chuo, Tokyo, Jpn
設立
2005
Daiichi Sankyo Co Ltd (PK) is listed in the Pharmaceutical Preparations sector of the その他OTC with ticker DSKYF. The last closing price for Daiichi Sankyo (PK) was US$28.54. Over the last year, Daiichi Sankyo (PK) shares have traded in a share price range of US$ 25.95 to US$ 44.64.

Daiichi Sankyo (PK) currently has 1,916,787,029 shares in issue. The market capitalisation of Daiichi Sankyo (PK) is US$54.70 billion. Daiichi Sankyo (PK) has a price to earnings ratio (PE ratio) of 0.30.

DSKYF 最新ニュース

Daiichi Sankyo's Once-Daily Lixiana® (edoxaban) Approved for the Prevention of Stroke and Systemic Embolism in Non-Valvular ...

Daiichi Sankyo's Once-Daily Lixiana® (edoxaban) Approved for the Prevention of Stroke and Systemic Embolism in Non-Valvular Atrial Fibrillation and for the Treatment and Prevention of Recurrent...

Daiichi Sankyo, Inc. and Asubio Pharmaceuticals, Inc. Merge

Daiichi Sankyo, Inc. and Asubio Pharmaceuticals, Inc. Merge PR Newswire PARSIPPANY, N.J., April 1, 2015 PARSIPPANY, N.J., April 1, 2015 /PRNewswire/ -- Daiichi Sankyo, Inc., the US subsidiary of...

Daiichi Sankyo, Inc. Names Danesha Dixon Smith Vice President of Human Resources

Daiichi Sankyo, Inc. Names Danesha Dixon Smith Vice President of Human Resources PR Newswire PARSIPPANY, N.J., June 28, 2011 PARSIPPANY, N.J., June 28, 2011 /PRNewswire/ -- Daiichi Sankyo, Inc...

John P. Gargiulo Named President and CEO of Daiichi Sankyo, Inc.

John P. Gargiulo Named President and CEO of Daiichi Sankyo, Inc. PR Newswire PARSIPPANY, N.J., April 4, 2011 PARSIPPANY, N.J., April 4, 2011 /PRNewswire/ -- Daiichi Sankyo, Inc. (DSI) announced...

Update: Daiichi Sankyo Completes Enrollment of the Edoxaban Global Phase III ENGAGE AF-TIMI 48 Study in Patients With Atrial Fib

Update: Daiichi Sankyo Completes Enrollment of the Edoxaban Global Phase III ENGAGE AF-TIMI 48 Study in Patients With Atrial Fibrillation - More Than 21,000 Patients Enrolled in the Largest...

Daiichi Sankyo Completes Enrollment of the Edoxaban Global Phase III ENGAGE AF-TIMI 48 Study in Patients With Atrial Fibrillatio

Daiichi Sankyo Completes Enrollment of the Edoxaban Global Phase III ENGAGE AF-TIMI 48 Study in Patients With Atrial Fibrillation - More Than 21,000 Patients Enrolled in the Largest Clinical...

ArQule and Daiichi Sankyo Expand Drug Discovery Collaboration in Oncology

ArQule and Daiichi Sankyo Expand Drug Discovery Collaboration in Oncology PR Newswire WOBURN, Massachusetts, October 12, 2010 WOBURN, Massachusetts, October 12, 2010 /PRNewswire/ -- ArQule, Inc...

Patients with Hypertension at Risk Due to Physician Inertia

Patients with Hypertension at Risk Due to Physician Inertia - New Supporting Hypertension Awareness and Research Europe-wide (SHARE) Survey Reports Findings at the 20th Annual Society of the...

Daiichi Sankyo Submits First New Drug Application for Oral Factor Xa Inhibitor, Edoxaban

Daiichi Sankyo Submits First New Drug Application for Oral Factor Xa Inhibitor, Edoxaban - Innovative Once-Daily Oral Factor Xa Inhibitor Submitted for Approval in Japan PR Newswire TOKYO, April...

Daiichi Sankyo, Inc. Names Dr. Jay Feingold Vice President, Medical Affairs

Bolsters Company's Expertise in Areas of Oncology and Hematology PARSIPPANY, N.J., Feb. 11 /PRNewswire-FirstCall/ -- Daiichi Sankyo, Inc. (DSI) announced today that Jay M. Feingold, M.D., Ph.D...

期間 †前日比前日比 %始値高値安値平均出来高VWAP
11.093.5784635587730.4633.0927.15674828.91900714CS
40.391.2516046213131.1634.627.15457830.91492183CS
12-6.89-17.92403746138.4444.6427.15346333.52745314CS
26-4.33-12.068004459335.8844.6427.15549334.50607706CS
524.9918.787650602426.5644.6425.951019631.65880671CS
1564.7217.592247484226.8344.6419.45802030.16840193CS
260-30.529411-49.177997194662.07941195.9617.61618930.10797516CS

ムーバー

すべて表示
  • 出来高
  • 値上がり率
  • 値下がり率
銘柄コード株価出来高
PDROPedros List Inc (CE)
US$ 0.0032
(319,900.00%)
31.17k
GBXIGBX International Group Inc (CE)
US$ 0.0002
(19,900.00%)
1.53k
TTCFQTattooed Chef Inc (CE)
US$ 0.0001
(9,900.00%)
54.21k
MGTIMGT Capital Investments Inc (CE)
US$ 0.0001
(9,900.00%)
457.82k
ATHCAccelerated Technologies Holding Corporation (CE)
US$ 0.0001
(9,900.00%)
173
AGDXFAntioqua Gold Inc (CE)
US$ 0.000001
(-100.00%)
60k
FGHFFForte Group Holdings Inc (PK)
US$ 0.0007
(-99.82%)
343
IGFFFInfinito Gold Ltd (CE)
US$ 0.000001
(-99.80%)
15k
EGRNFChina Evergrande Group (CE)
US$ 0.000001
(-99.67%)
500
LLBOLifeline Biotech Inc (CE)
US$ 0.000001
(-99.67%)
1.01M
NSAVNet Savings Link Inc (PK)
US$ 0.00105
(31.25%)
173.45M
RDARRaadr Inc (PK)
US$ 0.0008
(33.33%)
172.18M
AITXArtificial Intelligence Technology Solutions Inc (PK)
US$ 0.0035
(2.94%)
165.17M
HMBLHUMBL Inc (PK)
US$ 0.0003
(0.00%)
146.21M
CBDLCBD Life Sciences Inc (PK)
US$ 0.0005
(25.00%)
125.1M

最近閲覧した銘柄

Delayed Upgrade Clock